{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:33:19Z","timestamp":1792683199848,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102179","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:19:42Z","timestamp":1722046782000},"page":"102179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metastatic Tropism in Urothelial Carcinoma With Variant Histology: A Comprehensive NCDB Analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-6875","authenticated-orcid":false,"given":"Arthur","family":"Drouaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-4824","authenticated-orcid":false,"given":"Vincent","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-407X","authenticated-orcid":false,"given":"Ryan","family":"Antar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-8136","authenticated-orcid":false,"given":"Brandon","family":"Boyarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9362-3073","authenticated-orcid":false,"given":"Jacob","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2647-4848","authenticated-orcid":false,"given":"Diego","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2423-072X","authenticated-orcid":false,"given":"Michael J","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102179_bib0001","unstructured":"Cancer (IARC) TIA for R on. Global cancer observatory. Accessed March 23, 2024. https:\/\/gco.iarc.fr\/."},{"issue":"1","key":"10.1016\/j.clgc.2024.102179_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6 Suppl 1","key":"10.1016\/j.clgc.2024.102179_bib0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.clgc.2024.102179_bib0004","first-page":"749","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Med Kaunas Lith"},{"issue":"12","key":"10.1016\/j.clgc.2024.102179_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11934-018-0860-6","article-title":"Bladder cancer survivorship","volume":"19","author":"Bhanvadia","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"10","key":"10.1016\/j.clgc.2024.102179_bib0006","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.21037\/tcr-20-2169","article-title":"Variant histology in bladder cancer: diagnostic and clinical implications","volume":"9","author":"Black","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.clgc.2024.102179_bib0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2024.102179_bib0008","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CMAR.S148856","article-title":"Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study","volume":"9","author":"Dong","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102179_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2214\/AJR.10.5036","article-title":"Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor","volume":"196","author":"Shinagare","year":"2011","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102179_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular subtypes of bladder cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.clgc.2024.102179_bib0011","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5858\/arpa.2011-0463-OA","article-title":"Lymphovascular invasion in micropapillary urothelial carcinoma: a study of 22 cases","volume":"136","author":"McQuitty","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"9804","key":"10.1016\/j.clgc.2024.102179_bib0012","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.clgc.2024.102179_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2559.2004.01980.x","article-title":"Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases","volume":"46","author":"Abrahams","year":"2005","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.clgc.2024.102179_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskim\u00e4e","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102179_bib0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.clgc.2024.102179_bib0016","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.urology.2008.11.042","article-title":"Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?","volume":"73","author":"Scosyrev","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.clgc.2024.102179_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/iju.IJU_115_17","article-title":"Oncologic outcomes in patients with nonurothelial bladder cancer","volume":"34","author":"Patel","year":"2018","journal-title":"Indian J Urol IJU J Urol Soc India"},{"issue":"6","key":"10.1016\/j.clgc.2024.102179_bib0018","first-page":"2090","article-title":"Different patterns in the prognostic value of age for bladder cancer-specific survival depending on tumor stages","volume":"5","author":"Feng","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2024.102179_bib0019","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2004.04588.x","article-title":"Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment","volume":"93","author":"Shokeir","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2024.102179_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2152-7806.99172","article-title":"Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: case report and literature review","volume":"3","author":"Sarmiento","year":"2012","journal-title":"Surg Neurol Int"},{"issue":"3","key":"10.1016\/j.clgc.2024.102179_bib0021","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2007.10.069","article-title":"Prognostic impact of comorbidity in patients with bladder cancer","volume":"53","author":"Megwalu","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102179_bib0022","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urology.2016.01.048","article-title":"Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice","volume":"93","author":"Luchey","year":"2016","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.clgc.2024.102179_bib0023","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102179_bib0024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11934-019-0949-6","article-title":"Variant histology in bladder cancer-current understanding of pathologic subtypes","volume":"20","author":"Aron","year":"2019","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clgc.2024.102179_bib0025","unstructured":"Merck Sharp & Dohme LLC. A Phase III randomized, controlled clinical trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT02853305. Accessed December 31, 2023."},{"key":"10.1016\/j.clgc.2024.102179_bib0026","unstructured":"Astellas Pharma Global Development, Inc. An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT04223856. Accessed December 31, 2023."},{"key":"10.1016\/j.clgc.2024.102179_bib0027","unstructured":"Bristol-Myers Squibb. A phase 3, open-label, randomized study of nivolumab combined with ipilimumab, or with standard of care chemotherapy, versus standard of care chemotherapy in participants with previously untreated unresectable or metastatic urothelial cancer. clinicaltrials.gov;2024. https:\/\/clinicaltrials.gov\/study\/NCT03036098. Accessed December 31, 2023."},{"issue":"17","key":"10.1016\/j.clgc.2024.102179_bib0028","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102179_bib0029","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.clgc.2024.102179_bib0030","doi-asserted-by":"crossref","first-page":"13206","DOI":"10.3390\/ijms232113206","article-title":"Biomarkers of bladder cancer: cell-free DNA, epigenetic modifications and non-coding RNAs","volume":"23","author":"Harsanyi","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:58:25Z","timestamp":1738565905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001502"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102179","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic Tropism in Urothelial Carcinoma With Variant Histology: A Comprehensive NCDB Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102179"}}